Company and Corporate Business
Biolabs Inc. is a biomedical technology company that has formed a joint venture with Biotherapies Inc., of Ann Arbor, Michigan (a private company under the control of Dr. Paul Ervin Jr.). The latter is a biomedical research company which has made major progress in developing the use of the mammastatin protein in the field of treatment for breast cancer and the associated focus of exploring the use of mammastatin as a diagnostic blood test for detecting women at high risk for breast cancer. In addition to its 6% equity ownership in Biotherapies Inc, BioLabs has a joint venture agreement for the exclusive worldwide rights to develop, manufacture and distribute the Mammastatin Serum Assay (MSA) blood test. The MSA test is intended to quantify the levels of the mammastatin protein in an individuals blood sample and is thus anticipated to measure or evaluate breast cancer risk.
Research to date on a large number of human blood and breast tissue samples has consistently shown that mammastatin is a key inhibitor protein responsible for controlling abnormal cell growth in breast cell tissue. Mammastatin protein is present in the blood stream of healthy women and is either absent, or present in significantly reduced amounts, in over 90% of breast cancer patients tested to date. With the high incidence and mortality rate associated with breast cancer, the company strongly believes that there is a large global market for a diagnostic screening test that is quick, accurate, and easily administered as part of a woman's routine health care.
In addition to its anticipated diagnostic value, mammastatin has been shown to have potentially tremendous value both as a treatment therapy for breast cancer patients and as a potential preventative therapy for women at high risk for breast cancer. This joint venture is actively compiling its data base blood sampling for analysis in preparation for the development of all aspects of the Mammastatin Serum Assay (MSA).
Market Potential
Biolabs is an emerging participant in the multi-billion dollar biotechnology and medical technology industry. Breast cancer diagnostics and therapeutics represent a $10 billion industry. Research statistics indicate that an estimated one in eight women are expected to develop breast cancer in their lifetime. The U.S. alone currently has 3 million breast cancer patients and survivors.
Management
Aside from its significant and proprietary technologies, Biolabs Inc. can proudly boast its senior management and technical advisors to be a significant asset. The Company has meticulously assembled an experienced team of hands-on industry and business professionals to ensure Biolab's future success. Led by E. Greg McCartney, President and Chief Executive Officer, the Company has implemented an aggressive, yet cost sensitive approach to attaining its goal and is continuing to recruit professionals to the senior management and Board of Directors.
Mr. McCartney is a seasoned business veteran with more than 20 years of experience serving as Officer and Director of both private and public companies in various manufacturing and technology industries.
Dr. Ian B.Woods, Ph.D., MD., Vice President Operations, brings to the Company a strong scientific research and clinical medicine background encompassing the past 20 years. Dr. Woods completed his Ph.D. as a research physicist before entering the field of clinical medicine. Dr. Woods has served on the Medical Advisory, Pediatric Advisory, and Medical Manpower Committees at the Royal Columbian Hospital in New Westminster, Canada.
Lawrence J. Pasemko Secretary/Treasurer, possesses over 30 years of experience in business management, marketing, administration and a keen working knowledge of financial analysis and inventory controls.
Dr. Paul Ervin Jr., Ph.D., a Company director is Founder and Managing Director of the Mammastatin Research Institute, and former Research Scientist at the University of Michigan Cancer Research Center. Dr. Ervin is the principal scientist who's research at the University of Michigan in the mid 1980's first revealed the association of Mammastatin as a key protein involved in controlling abnormal breast cancer growth.
Outlook
Biolabs is extremely well positioned to benefit from its diversified exposure to breakthrough medical technologies. The Company's principal interest is its MSA diagnostic test being developed in conjunction with Dr. Paul Ervin Jr. Mammastatin however, has also been shown to be effective as a potential treatment therapy. Interestingly, research to date on over 29 late stage IV breast cancer patients has shown that when these women are given mammastatin protein by I.V. injection, that over 70% show positive response in both their local and metastatic cancerous tumours.
Product
The Company, through its joint venture with Biotherapies Inc, will develop and operate a laboratory to manufacture the mammastatin antibody reagent for the anticipated MSA test kit.
Additional Information
Health & Welfare Canada has approved them to do compassionate therapy of Mammastatin in women with very advanced stage breast cancer at certain hospitals in Canada.
A initial financing was done at $3 U.S.
These funds will be used to help finance further research and development. They will also provide working capital and help construct the diagnostics lab which will initially be used for commercial purposes and to complete a larger blood test program on women at high risk of breast cancer.
Due Diligence (technical data)
Mammastatin Research Institute
members.aol.com
University of Michigan
cancer.med.umich.edu
American Cancer Society
cancer.org
Institute of Cancer Research
icr.ac.uk
Links
Company's Website
biolabs.com
Delayed Quotes
quote.yahoo.com
Real Time Quotes
freerealtime.com
News Search Engine
biz.yahoo.com
Chart
bigcharts.com
OTC-BB
otcbb.com |
